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Recent developments in positron emission tomography
(PET) and single-photon emission computed tomogra-
phy (SPECT) imaging have enabled functional measure-
ments of dopamine (DA) transmission at dopamine D2
receptors in the living human brain. Studies using these
techniques have demonstrated that, in schizophrenia,
increased DA stimulation of striatal D2 receptors is asso-
ciated with the first episode of illness and subsequent
episodes of illness exacerbation. While this dysregula-
tion of DA function is not associated with the severity of
positive symptoms per se, increased synaptic DA activity
is predictive of good therapeutic response to antipsy-
chotic treatment. Abnormalities of DA function were
not detected during periods of illness remission. These
findings are integrated into a clinical model proposing
that, in schizophrenia, neurodevelopmental abnormali-
ties of cortico-subcortical connectivity result in a vulner-
ability of the mesolimbic DA system to the development
of a process of endogenous sensitization, and that the
resulting sustained hyperstimulation of D2 receptors
induces neuroplastic changes within corticostriatal-thal-
amocortical loops, perturbing information processing
and underlying the psychotic experience.
he “classical” dopamine (DA) hypothesis of
schizophrenia proposed that hyperactivity of DA trans-
mission is responsible for the positive symptoms (hallu-
cinations, delusions) observed in this disorder.
1 This
hypothesis was supported by the correlation between
clinical doses of antipsychotic drugs and their potency
for blocking DA D2 receptors,
2,3 and by the psychoto-
genic effects of DA-enhancing drugs (for reviews, see
references 4 and 5). These critical pharmacological
observations suggested,but did not establish,a dysregu-
lation of DA systems in schizophrenia.
On the other hand, negative and cognitive symptoms
are generally resistant to treatment by antipsychotic
drugs.Impairment in higher cognitive functions,such as
working memory,is one of the most enduring symptoms
of schizophrenia and a strong predictor of poor clinical
outcome.
6 Functional brain-imaging studies suggested
that these symptoms are associated with a dysfunction of
the prefrontal cortex (PFC).
7-9 Studies in nonhuman pri-
mates demonstrated that deficit in DA transmission in
the PFC and lack of stimulation of D1 receptors (the
main DA receptor subtype in the PFC) induce cogni-
tive impairments reminiscent of those observed in
patients with schizophrenia.
10 Together, these observa-
tions suggest that a deficit in DA transmission at D1
receptors in the PFC might be implicated in the cogni-
tive impairments presented by these patients.
9
Thus,the current view on DA and schizophrenia proposes
that schizophrenia might be associated with a dopamin-
ergic imbalance involving an excess of subcortical DA
and a deficit in cortical DA function:subcortical mesolim-
bic DA projections might be hyperactive (resulting in
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Pharmacological aspectshyperstimulation of D2 receptors and positive symptoms)
and mesocortical DA projections to the PFC might be
hypoactive (resulting in hypostimulation of D1 receptors,
negative symptoms,and cognitive impairment).
9,11
Despite decades of effort to validate these hypotheses,
documentation of abnormalities of DA function in schiz-
ophrenia has remained elusive.Postmortem studies mea-
suring DA and its metabolites and receptors in the
brains of schizophrenic patients have yielded inconsis-
tent or inconclusive results (for a review, see reference
11).The lack of clear evidence for altered dopaminergic
indices in schizophrenia might indicate that DA trans-
mission is abnormal only relative to other systems,such
as the glutamatergic system.
12 On the other hand, the
absence of data supporting the DA hypothesis of schiz-
ophrenia might be due to the difficulty in obtaining a
direct measurement of DA transmission in the living
human brain.
However,over the last few years,progress in brain-imag-
ing methods has enabled direct measurement of DA
transmission at the D2 receptor, and the application of
these techniques to the study of schizophrenia has pro-
vided new insights into the nature and the role of DA
function dysregulation in schizophrenia.This paper will
briefly review these data,and explore the implications of
these results in terms of pathophysiology and treatment.
Brain imaging as a tool for measuring DA
synaptic activities
Neuroreceptor imaging with positron emission tomog-
raphy (PET) and single-photon emission computed
tomography (SPECT) are classically aimed at measuring
neuroreceptor parameters in the living human brain.
More recently, several groups have demonstrated that
under specific conditions, in vivo neuroreceptor bind-
ing techniques can also be used to measure acute fluc-
tuations in the concentration of the endogenous trans-
mitters in the vicinity of radiolabeled receptors.
13-16
Competition between radiotracers and transmitters for
binding to neuroreceptors is the principle underlying
this technique, though other mechanisms such as ago-
nist-induced receptor internalization might also play a
role (for a review,see reference 17).So far,applications
of this new paradigm have been developed mainly to
study DA transmission at D2 receptors.
Endogenous competition between DA and radiolabeled
D2 receptor ligands was initially documented in ex vivo
studies performed in rodents. Amphetamine, which
releases DA and thereby increases endogenous DA
synaptic concentration,
18,19 reduced the in vivo binding of
the D2 agonist [
3H]-N-propylnorapomorphine
20,21 and the
D2 antagonist [
3H]raclopride.
22,23 Reduced in vivo accu-
mulation of D2 tracers was also reported following pre-
treatment with the DA uptake inhibitors amfonelic acid
and methylphenidate.
21The opposite effect (ie,increased
tracer accumulation) was induced by drugs that decrease
DA endogenous concentration, such as reserpine and 
γ -butyrolactone.
21,23-26
These interactions suggested that PET and SPECT
could be used to measure acute fluctuations in endoge-
nous DA.In baboons,the binding potential (BP) of var-
ious dopamine D2 radiotracers was decreased by drugs
that increase DA synaptic concentration, such as
amphetamine,
13,14,16,27-30 cocaine,
31 or GBR 12909.
32
Increased radiotracer uptake was observed following
drugs that reduce DA availability,such as reserpine
33 or
γ -vinyl-γ -aminobutyric acid (γ -vinyl-GABA).
34 These
interactions were also reported in humans: decreased
specific binding of [
11C]raclopride or [
123I]iodobenzamide
([
123I]IBZM) was reported following acute administra-
tion of the DA-enhancing drugs methylphenidate,
35,36
amphetamine,
37,38 cocaine,
39 and even cognitive chal-
lenges.
40 Conversely,increased [
123I]IBZM BP was docu-
mented following DA depletion with the reversible tyro-
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Selected abbreviations and acronyms
BP binding potential
DA dopamine
DAT dopamine transporter
DLPFC dorsolateral prefrontal cortex
DOPA dihydroxyphenylalanine
GABA  -aminobutyric acid
IBZM iodobenzamide
ICC intraclass correlation coefficient 
LSD lysergic acid diethylamide
MAM methylazoxymethanol
 -MPT  -methyl-para-tyrosine
NAA N-acetylaspartate
NMDA N-methyl-D-aspartate
PET positron emission tomography 
PFC prefrontal cortex
SPECT single-photon emission computed tomography
VTA ventral tegmental area361
sine hydroxylase inhibitor α -methyl-para-tyrosine (α -
MPT).
41
The amphetamine-induced reduction in [
123I]IBZM or
[
11C]raclopride BP to D2 receptors has been well vali-
dated as an indirect measure of the change in synaptic
DA concentration induced by the challenge. The first
step was to establish that the amphetamine-induced
reduction in radiotracer BP was mediated by DA
release,and not by some indirect effect of amphetamine
unrelated to DA release.The mediation of the amphet-
amine effect by DA release was demonstrated by estab-
lishing that pretreatment with the tyrosine hydroxylase
inhibitor α -MPT blocked the effect of amphetamine on
[
123I]IBZM BP.
14 More recently,Villemagne et al
42 showed
that pretreatment with the dopamine transport (DAT)
blocker GBR 12909 (a drug that prevents amphetamine-
induced DA release) blocked the effect of amphetamine
on [
11C]raclopride BP.The second step was to study the
relationship between the magnitude of DA release and
the reduction in radiotracer BP,to assess the potential of
the imaging measurement to provide a quantitative mea-
sure of DA release.This comparison was accomplished
in primates by comparing amphetamine-induced DA
release measured with microdialysis and reduction of
radiotracer binding measured with PET or SPECT fol-
lowing various doses of amphetamine.
14,38 These studies
demonstrated that the reduction in radiotracer BP was
linearly correlated with the peak DA release measured
with microdialysis.This observation validated the use of
this noninvasive paradigm to measure changes in synap-
tic DA following amphetamine,and provided an opera-
tional calibration of the imaging signal.We also evalu-
ated the reproducibility of the SPECT measurement of
the amphetamine effect on D2 receptor BP.We observed
an excellent reproducibility of the measurement,both in
baboons, where the intraclass correlation coefficient
(ICC) was 0.97,
14 and in humans, where the ICC was
0.89.
43 Together, these results supported the feasibility
of measuring amphetamine-induced DA release in
humans with this noninvasive technique.
Imaging amphetamine-induced 
DA release in schizophrenia
We and others adopted this imaging technique to mea-
sure amphetamine-induced DA release in patients with
schizophrenia and matched healthy controls.
38,44-46 Our
final sample consisted of 34 patients with schizophrenia
and 36 matched healthy controls.
46 Patients met Diag-
nostic and Statistical Manual of Mental Disorders–IV
(DSM-IV) criteria for schizophrenia,and were carefully
screened to exclude any patients with a history of drug or
alcohol abuse or dependence. Healthy controls were
matched for gender, age, race, and parental socioeco-
nomic status. Patients had been off medication for at
least 21 days at the time of the study. Seven were neu-
roleptic naive,experiencing a first episode of the illness.
Patients were recruited under two modalities.Seventeen
patients were recruited shortly after admission to the
hospital for clinical reasons and were experiencing an
episode of clinical deterioration at the time of recruit-
ment.In all cases,the admission was voluntary.The other
17 patients were recruited in outpatient clinics. These
patients were in a stable phase of the illness, and were
admitted to the hospital only for the purpose of the study.
In the control subjects,the amphetamine-induced reduc-
tion in [
123I]IBZM BP was 7.5±7.1% (n=36). Compared
with the controls, the patients with schizophrenia dis-
played a marked elevation of amphetamine-induced
[
123I]IBZM displacement (17.1±13.2%, n=34, P=0.0003,
Figure 1).A similar finding has been reported by Breier
et al
38 using [
11C]raclopride, PET, and a smaller dose of
amphetamine (0.2 mg/kg,intravenously).This increased
effect of amphetamine on [
123I]IBZM BP in patients with
schizophrenia was not related to differences in amphet-
amine plasma disposition, since amphetamine plasma
levels were similar in both groups. Providing that the
affinity of D2 receptors for DA is unchanged in this ill-
ness (see discussion in reference 46),these data are con-
sistent with an increased amphetamine-induced DA
release in schizophrenia.
The amphetamine effect on [
123I]IBZM BP was similar in
chronic/previously treated patients (16.2±13.5%, n=27)
and first-episode/neuroleptic-naive patients (20.9±12.2%,
n=7,P=0.41),and both groups were significantly different
from controls.In the previously treated group,no associ-
ation was found between the duration of the neuroleptic-
free period and the amphetamine-induced [
123I]IBZM
displacement (r=0.02, P=0.91). Together, these results
indicated that the exaggerated dopaminergic response
to amphetamine exposure was not a prolonged side
effect of previous neuroleptic exposure.
In patients with schizophrenia, the amphetamine chal-
lenge induced a significant increase in positive symp-
toms.The emergence or worsening of positive symptoms
was transient, and patients returned to their baseline
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symptomatology within a few hours of the challenge.
We observed a significant correlation between the
increase in positive symptoms and the [
123I]IBZM dis-
placement (r=0.54,P=0.0009).This result provides direct
evidence that exaggerated activation of DA transmis-
sion at D2 receptors mediates the expression of psy-
chotic symptoms following amphetamine challenge.
However, DA-mediated stimulation of D2 receptors
explained only about 30% of the variance in the positive
symptom changes, indicating that other factors play a
role in the exacerbation of these symptoms following
amphetamine.
We tested associations between the amphetamine effect
on [
123I]IBZM BP and several demographic and clinical
variables in the group of patients with schizophrenia, in
an attempt to characterize the profile of patients with
exaggerated response.Symptom severity per se (whether
positive or negative symptoms) at baseline was not pre-
dictive of the amphetamine effect on D2 receptor trans-
mission.No association was found between the amphet-
amine effect and age,gender,race,subject socioeconomic
status, familial socioeconomic status, duration of illness,
or number of previous hospitalizations. However,
patients who were experiencing an illness exacerbation
(identified by the fact that their admission was motivated
by clinical reasons) presented a higher amphetamine-
induced [
123I]IBZM displacement (23.7±13.2%, n=17)
than patients who were in remission and recruited as
outpatients (10.5±9.7%, n=17, P=0.002). Furthermore,
amphetamine-induced [
123I]IBZM displacement in remit-
ted patients (10.5±9.7%, n=17) was not statistically dif-
ferent from controls (7.5±7.1%, n=36, P=0.27). This
observation suggests that dysregulation of DA release
in patients with schizophrenia might be present only dur-
ing episodes of illness exacerbation. Studying the same
patients during exacerbation and remission phases is
required to confirm this point.
An important question raised by these studies is
whether the stress associated with psychiatric hospital-
ization and/or the scanning procedure might account for
the excess DA release measured in patients with schiz-
ophrenia,since stress activates DA release.
47,48To inves-
tigate this potential confounding factor, we recently
studied amphetamine-induced DA release in a group of
nonpsychotic unipolar depressed subjects (n=9).
49
Patients from both groups (patients with schizophrenia
and patients with unipolar depression) were experienc-
ing a severe psychiatric episode, had recently been
admitted to the unfamiliar environment of a research
ward, and were untreated at the time of the scan.
Despite reporting elevated anxiety levels, the patients
with depression did not show elevated activation of the
DA system by amphetamine (amphetamine-induced dis-
placement of [
123I]IBZM in depressed subjects was
9.8±5.5%, not significantly different from their control
subjects, 7.8±2.5%, P=0.38). This finding supports the
hypothesis that the increased amphetamine effect
observed in patients with schizophrenia is not a non-
specific consequence of stressful conditions (although
it could represent a specific interaction between stress
and schizophrenia).
The data reviewed above are consistent with higher
DA output in the striatum of patients with schizo-
phrenia,which could be explained by increased density
of DA terminals. Since striatal DATs are exclusively
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Figure 1. Effect of amphetamine (0.3 mg/kg) on [
123I]iodobenza-
mide ([
123I]IBZM) binding in healthy controls and untreat-
ed patients with schizophrenia. The y axis shows the per-
centage decrease in [
123I]IBZM binding potential induced
by amphetamine, which is a measure of the increased
occupancy of dopamine D2 receptors by dopamine fol-
lowing the challenge. Increased stimulation of D2 recep-
tors in schizophrenia was associated with transient wors-
ening or emergence of positive symptoms.
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localized on DA terminals, this question was investi-
gated by measuring binding of the DAT radioligands
[
123I]-2β -carbomethoxy-3β -(4-iodophenyl)tropane
([
123I]β -CIT)
50 or 2β -carbomethoxy-3β -(4-[
18F]fluoro-
phenyl)tropane ([
18F]CFT)
51 in patients with schizo-
phrenia. Neither study reported a difference in DAT
binding between patients and controls. In addition,
Laruelle et al
50 reported no association between
amphetamine-induced DA release and DAT density.
Thus, the increased presynaptic output suggested by
the amphetamine studies does not appear to be due to
higher terminal density.This observation is consistent
with postmortem studies,which failed to identify alter-
ations in striatal DAT binding in schizophrenia.
52-57
Imaging baseline DA 
activity in schizophrenia
A major limitation of the amphetamine studies is that
they measured changes in synaptic DA transmission fol-
lowing a nonphysiological challenge (ie, amphetamine)
and did not provide any information about synaptic DA
levels at baseline, ie, in the unchallenged state. Mea-
surement of baseline synaptic levels of DA required the
development of another imaging strategy.As discussed
above, several laboratories reported that, in rodents,
acute depletion of synaptic DA is associated with an
acute increase in the in vivo binding of [
11C]raclopride or
[
123I]IBZM to D2 receptors. The increased binding was
observed in vivo but not in vitro, indicating that it was
not due to receptor upregulation,
41 but to removal of
endogenous DA and unmasking of D2 receptors previ-
ously occupied by DA. Based on these preclinical data,
an acute DA depletion challenge was developed in
humans using α -MPT,to assess the degree of occupancy
of D2 receptors by DA.
41
Using this strategy,we studied baseline occupancy of D2
receptors by DA in patients with schizophrenia com-
pared with healthy control subjects.
58 D2 receptor avail-
ability was measured at baseline (ie, in the absence of
any pharmacological intervention) and during acute DA
depletion.Acute DA depletion was achieved by admin-
istration of high doses of α -MPT for 2 days.
59,60 Since this
duration of treatment is too short to induce detectable
D2 receptor upregulation, the main difference between
D2 receptor availability measured at baseline and in the
depleted state is due to the unmasking of D2 receptors
previously occupied by DA.
41 Therefore, comparing 
D2 receptor availability at baseline and in the depleted
state provided an indirect measure of the proportion of
D2 receptors occupied by DA in the baseline state.
Patients (n=18) and controls (n=18) were matched on
age, gender, parental socioeconomic status, cigarette
smoking, and weight. Among the 18 patients, 8 were
antipsychotic-naive and experiencing a first episode of
illness. All patients were experiencing an episode of
acute illness exacerbation.
Removal of endogenous DA by α -MPT increased D2
receptor availability by 9±7% in controls and 19±11% in
patients with schizophrenia (P=0.003).The differential
effect of α -MPT between patients and controls was not
due to differences in α -MPT bioavailability. α -MPT
plasma levels were not different in controls (19±6
µg/mL) and patients (21±6 µg/mL,P=0.522).The α -MPT
effect on D2 receptor availability was not statistically
different between drug-naive (n=8, 17±6%) and previ-
ously treated patients (n=10,20±15%),and both groups
were significantly different from controls.
Thus,the results of this study suggest that DA occupies a
greater proportion of striatal D2 receptors in patients
with schizophrenia compared with matched control sub-
jects during the first episode of illness and subsequent
episodes of illness exacerbation.The significance of this
result stems from the fact that the paradigm used here
reveals D2 receptor occupancy by DA during the base-
line scan,ie,in the absence of any pharmacological inter-
vention. The results of the α -MPT study are consistent
with results of studies reporting rates of dihydroxy-
phenylalanine (DOPA) decarboxylase activity in patients
with schizophrenia,using [
18F]DOPA
61-64 or [
11C]DOPA.
65
Four out of five studies reported increased accumulation
of DOPA in the striatum of patients with schizophrenia,
and the combined analysis of these studies yields an
effect size of 0.92±0.45, which is significantly different
from zero (P=0.01). While the relationship between
DOPA decarboxylase and DA synthesis rate is unclear
(DOPA decarboxylase is not in the rate-limiting step of
DA synthesis),these observations are consistent with the
higher synaptic DA concentration observed in patients
with schizophrenia in the α -MPT study.
In patients,α -MPT significantly reduced positive symp-
toms, and high baseline DA was predictive of good
response of positive symptoms to α -MPT. However,
baseline global severity of positive symptoms was not
associated with high DA synaptic concentration at
baseline. Among positive symptoms, only severity ofsuspiciousness was associated with a trend toward high
synaptic DA levels (r
2=0.19, P=0.07). This negative
result might be due to the limited resolution of the
SPECT camera. Considerable preclinical evidence
from rodent studies supports the hypothesis that
antipsychotic drug action is associated with D2 recep-
tor antagonism in the mesolimbic (ventral striatal,
including nucleus accumbens) rather than the nigro-
striatal (dorsostriatal) DA systems (for a review, see
reference 66). The limited resolution of the SPECT
camera prevented us from distinguishing the respec-
tive contributions of the ventral and dorsal striata to
the SPECT signal.Studies with a high-resolution PET
camera are needed to clarify this point.
On the other hand, this negative result might indicate
that the severity of positive symptoms rated cross-sec-
tionally by the Positive and Negative Syndrome Scale
(PANSS) depends mostly on factors located downstream
from the mesolimbic dopaminergic synapses. The dys-
functional neuronal circuits that underlie the experience
of positive symptoms are likely to involve dysregulated
prefrontal-ventrostriatal-ventropallidal-mediodorsal-
thalamoprefrontal loops, and their regulation by hip-
pocampal and amygdaline afferents.
67,68The results of the
studies reviewed here directly confirm that these loops
are under modulatory influence of subcortical DA.
A sudden rise in subcortical DA (such as that measured
following amphetamine) will exacerbate these symp-
toms, while a sudden decline in DA (such as measured
following α -MPT) will blunt their intensity. Thus, psy-
chotic symptomatology includes both DA-dependent
and DA-independent components, with the respective
contributions of each component varying from patient to
patient (and presumably varying with time within the
same patient).
Fourteen out of the 18 patients agreed to complete the 6
weeks’ period of antipsychotic medication as inpatients
(4 patients elected to be treated as outpatients and were
excluded from the treatment phase of the study).Com-
pared with baseline, a significant decrease in positive
symptoms was measured after 6 weeks of treatment
(P<0.0001). Changes in negative symptoms were not
significant. A large between-subject variability was
observed in the improvement of positive symptoms at 6
weeks (28±16%).Higher synaptic levels of DA at base-
line, as measured by the α -MPT effect on D2 receptor
BP, were significantly associated with greater improve-
ment in positive symptoms following 6 weeks of antipsy-
chotic treatment (r
2=53,P=0.0029).Thus,the dysregula-
tion of DA transmission revealed by the imaging study
was predictive of better response of positive symptoms
to antipsychotic treatment.Schizophrenic patients who
experienced positive symptoms in the presence of
increased DA stimulation of D2 receptors showed a
remarkable and rapid decline in these symptoms fol-
lowing treatment with antipsychotic drugs.On the other
hand, subjects who experienced positive symptoms in
the presence of apparently normal stimulation of D2
receptors by DA showed little improvement in these
symptoms following 6 weeks of antipsychotic treatment.
The fact that high levels of synaptic DA at baseline pre-
dicted a better or faster response to atypical antipsy-
chotic drugs (13 out of 14 patients were treated with
atypical drugs) also suggests that the D2 receptor block-
ade induced by these drugs remains a key component of
their initial mode of action.
Contrary to widely accepted views, antipsychotic drugs
have only partial efficacy against positive symptoms.A
substantial proportion of schizophrenic patients, possi-
bly a third, remain actively psychotic despite appropri-
ate and prolonged blockade of D2 receptors.
69,70The data
presented in this study suggest that, in some patients,
blockade of D2 receptors by antipsychotic drugs fails to
significantly alter positive symptoms because these
symptoms might not be related to excessive stimulation
of these receptors by DA.
Cortical regulation of subcortical 
DA transmission
While the studies reviewed above generally confirmed
the classical DA hypothesis of schizophrenia,it is impor-
tant to examine these results in light of the more recent
views of schizophrenia as a neurodevelopmental illness,
involving dysconnectivity of multiple cortico-subcortical
and intracortical networks. While it cannot be defini-
tively ruled out that the DA dysregulation revealed by
these studies stems from a primary abnormality of DA
neurons, it seems more likely that these abnormalities
are a consequence of cortico-subcortical dysconnectivity.
Moreover,given the weight of evidence implicating PFC
connectivity as a central deficient node in the schizo-
phrenic brain, it is tempting to speculate that a dysreg-
ulation of the firing activity of dopaminergic neurons
might stem from a failure of the PFC to regulate this
process. In fact, it has long been hypothesized that dys-
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364regulation of subcortical DA function in schizophre-
nia may be secondary to a failure of the PFC to ade-
quately control subcortical dopaminergic function.
71,72
In patients with schizophrenia, a low N-acetylaspartate
(NAA) concentration in the dorsolateral prefrontal cor-
tex (DLPFC), a marker of DLPFC pathology, is associ-
ated with increased amphetamine-induced DA release.
73
This result provides evidence that disinhibition of sub-
cortical DA activity is associated with prefrontal pathol-
ogy in schizophrenia.
According to a model introduced by Carlsson,
74 the
activity of midbrain DA neurons is under dual influence
of PFC via an activating pathway (the “accelerator”)
and an inhibitory pathway (“the brake”), allowing fine
tuning of dopaminergic activity by the PFC (Figure 2).
The activating pathway is provided by indirect gluta-
matergic projections onto the dopaminergic cells (indi-
rect projections likely involve the pedunculopontine
tegmentum
75). The inhibitory pathway is provided by
glutamatergic projections to midbrain GABAergic
interneurons or striatomesencephalic GABAergic neu-
rons.The inhibition of dopaminergic cell firing following
amphetamine is an important feedback mechanism by
which the brain reduces the effect of amphetamine on
DA release. The inhibition of dopaminergic cell firing
induced by amphetamine is mediated both by stimula-
tion of presynaptic D2 autoreceptors, and by stimula-
tion of this inhibitory pathway.
76
Following administration of amphetamine (ie, under
conditions in which the inhibitory pathway should be
activated), N-methyl-D-aspartate (NMDA) receptor
blockade results in a failure of activation of the
inhibitory pathway, resulting in exaggerated ampheta-
mine-induced DA release.
77 Kegeles et al
78 recently con-
firmed this mechanism in humans: pretreatment with
the noncompetitive NMDA antagonist ketamine signif-
icantly enhanced amphetamine-induced (0.25 mg/kg)
decrease in [
123I]IBZM BP,from -5.5±3.5% under control
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Figure 2. Model of modulation of ventral tegmental area dopamine (DA) cell activity by the prefrontal cortex (PFC). The activity of mid-
brain DA neurons is under the dual influence of PFC via activating and inhibitory pathways, allowing fine tuning of dopamin-
ergic activity by the PFC. The activating pathway is provided by glutamatergic projections onto the dopaminergic cells, and the
inhibitory pathway is provided by glutamatergic projections to midbrain γ -aminobutyric acid (GABA)-ergic interneurons or stri-
atomesencephalic GABA neurons. See text for description and references. This model predicts that a deficiency in N-methyl-D-
aspartate (NMDA) transmission (lesion 1) and/or GABA PFC function (lesion 2) and/or DA PFC function (lesion 3) would result in
a failure of the PFC to inhibit subcortical DA activity under conditions of excessive stimulation (such as stress or amphetamine
challenge). GLU: glutamate.
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+conditions to -12.8±8.8% with ketamine pretreatment
(P=0.023). The increase in amphetamine-induced DA
release with ketamine (greater than 2-fold) was compa-
rable in magnitude to the exaggerated response seen in
patients with schizophrenia. These data are consistent
with the hypotheses that (i) the alteration of DA release
revealed by the amphetamine challenge in schizophrenia
results from a disruption of glutamatergic neuronal sys-
tems regulating dopaminergic cell activity;and (ii) schiz-
ophrenia might be associated with NMDA receptor
hypofunction.
79-81
The failure of glutamatergic control of DA release might
stem from mechanisms other than NMDA hypofunc-
tion. For example, glutamatergic projections from the
PFC to the VTA are under tonic inhibition by prefrontal
GABA and DA activity (see reference 82 and refer-
ences therein).It follows that deficits in GABAergic or
dopaminergic function in the PFC (both of these deficits
are also implicated in schizophrenia) are expected to
have similar consequences to an NMDA deficiency on
the subcortical DA response to amphetamine. Thus, in
patients with schizophrenia,various or multiple mecha-
nisms (NMDA receptor hypofunction, GABAergic or
dopaminergic deficits in the PFC) may lead to the dys-
regulation of subcortical DA revealed by the ampheta-
mine challenge (Figure 2).
Moreover,preclinical studies documented that dysreg-
ulation of subcortical DA function might be a delayed
and enduring consequence of neurodevelopmental
abnormalities of limbic-cortical connectivity. Studies
in rodents showed that alteration of cortico-limbic
development induced by prenatal exposure to the
antimitotic agent methylazoxymethanol (MAM)
acetate results in increased subcortical DA release in
adulthood.
83 The increase in subcortical DA transmis-
sion in MAM-treated rodents was correlated strongly
with the severity of cerebral cortical thinning result-
ing from altered development.Adult rhesus monkeys
with neonatal ablation of the amygdala-hippocampal
formation exhibit lower NAA concentrations in the
PFC and impaired PFC inhibition of subcortical DA
functions.
84,85
Schizophrenia and 
endogenous sensitization
While the evidence reviewed above is consistent with
the model that dysregulation of subcortical DA func-
tion in schizophrenia is an enduring consequence of neu-
rodevelopmental abnormalities involving cortico-sub-
cortical dysconnectivity, this model fails to account for
the episodic nature of this dysregulation.In the imaging
studies reviewed above,abnormalities of subcortical DA
function as revealed by elevated amphetamine-induced
DA release was observed in patients experiencing a first
episode of illness or an episode of illness exacerbation,
but not in patients studied during a period of illness
remission.
Neurochemical sensitization of mesolimbic DA systems
has been proposed by several authors as one mechanism
that might underlie the progression of a “silent” vulner-
ability into an overt symptomatology, resulting in fur-
ther “toxic” effects on the brain.
86-90  Sensitization is a
process whereby exposure to a given stimulus, such as a
drug or a stessor,results in an enhanced response to sub-
sequent exposures.This phenomenon has been well char-
acterized in rodents:repeated exposure to psychostimu-
lants, such as amphetamine, induces an increase in the
behavioral (locomotion) and biochemical (DA release)
response to amphetamine, other stimulants, or stressors
(for reviews, see references 89 and 91–93). Sensitization
can be conceived of as a form of learning behavior,but its
adaptative value is not apparent. Sensitization is essen-
tially a nonhomeostatic, positive feedback mechanism,
and makes individuals more vulnerable rather than more
resistant to a number of pharmacological or environ-
mental stimulations.
The brain-imaging data reviewed above provide sup-
port for the hypothesis that dysfunction of DA systems
in schizophrenia results from a process similar to the
sensitization phenomenon described following repeated
psychostimulant exposure, because both conditions are
associated with increased psychostimulant-induced DA
release. Since patients included in the study had not
been previously exposed to psychostimulants, the
enhanced behavioral (psychotic reaction) and biochem-
ical (DA release) response might result from an
“endogenous”sensitization process.
Neurodevelopmental abnormalities associated with
schizophrenia may set the stage for the development of
an endogenous sensitization process.
88,94 We have
reviewed elsewhere
94 the preclinical literature suggesting
that early brain lesions that affect the development of
cortical connectivity result in enhanced vulnerability to
sensitization of mesolimbic DA systems. During late
adolescence,the failure of cortical development in schiz-
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late stress-related increased activity of mesolimbic DA
neurons.This failure of normal homeostatic and buffer-
ing mechanisms results in an increased vulnerability of
DA neurons to the development of a process of endoge-
nous sensitization, a response not observed in humans
under normal circumstances.While increased DA activ-
ity is initially associated with environmental stressors,
the sensitization process is self-perpetuating, and,
beyond a given threshold, becomes independent of the
environmental factors responsible for its initiation.This
positive feedback loop,in which more DA leads to more
DA, ultimately results in a clinical episode and in the
expression of positive symptoms.
Chronic blockade of D2 receptors and/or neuroleptic-
induced depolarization blockade of dopaminergic neu-
rons might allow a progressive extinction of this sensi-
tized state.This proposition is suggested by the failure to
detect an increase in amphetamine-induced DA release
in currently untreated patients with schizophrenia dur-
ing periods of stabilization. However, the high rate of
relapse during prolonged treatment discontinuation sug-
gests that this endogenous sensitization process might
resume upon environmental, physiological, or pharma-
cological stress.
DA hyperactivity, neuroplasticity, 
and positive symptoms
The data derived from the brain-imaging studies
reviewed above are consistent with the hypothesis that
subcortical DA transmission mediates the expression of
positive symptoms in patients with schizophrenia.How-
ever,the data also suggest that a component of the pos-
itive symptomatology is independent of increased activ-
ity of subcortical DA transmission. First, as discussed
earlier, the increase in DA transmission at striatal D2
receptors following amphetamine explained only 30% of
the variability in the psychotic response to d-ampheta-
mine.Second,the severity of positive symptoms was not
associated with increased synaptic DA concentration as
revealed by the α -MPT challenge. Thus, a simple rela-
tionship between intensity of DA transmission at the D2
receptors and severity of positive symptoms is an over-
simplification.
In addition, such a simple relationship is not supported
by the delay between D2 receptor blockade and antipsy-
chotic response,or by resistance of positive symptoms to
even sustained dopaminergic blockade in about 25% of
patients with schizophrenia.
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In this context,it is also important to note a critical dif-
ference in the propsychotic effects of DA agonists, on
the one hand, and NMDA antagonists or serotonin 
5-HT2A agonists, on the other. In healthy individuals,
drugs such as ketamine or lysergic acid diethylamide
(LSD) induce a psychotic state immediately upon drug
exposure,while sustained administration of DA agonists
is required for the emergence of psychotic symptoms
(for a review, see reference 95). This unique effect of
DA agonists suggests that some plasticity or neuroad-
aptation is required between the hyperstimulation of D2
receptors and the psychotic experience.
To account for these data,one must postulate that,with
time, increased DA activity triggers neuroplastic adap-
tation “downstream”from the mesolimbic dopaminergic
synapse and that, once established, these neuroplastic
changes become independent of increased DA activity.
Positive symptoms circuits might become “hard wired”
in prefrontal-ventrostriatal-ventropallidal-mediodorsal-
thalamoprefrontal loops
67,96 (Figure 3). Excessive DA
stimulation maintains the potential to activate these neu-
ronal ensembles (as demonstrated by the relationship
between D2 receptor stimulation and worsening of pos-
itive symptoms),but the evidence suggests that,at least
in some patients, these symptoms might become inde-
pendent of continuous DA stimulation (as demonstrated
by the observation that some patients exhibit severe
positive symptoms in the absence of detectable abnor-
malities in synaptic DA).Thus, the emergence of treat-
ment-resistant positive symptoms suggests that these
symptoms have taken on “a life of their own,” ie, have
become independent of DA stimulation.A better under-
standing of the consequences of sustained dopaminergic
activity on the plasticity of prefrontal-striatothalamic
loops is needed to further characterize the neurobiolog-
ical effects of sustained hyperdopaminergic state.
The ubiquitous role of DA in the creation of these hypo-
thetical psychotic ensembles remains to be established.
Whether DA hyperactivity has been present at some
point or another in the life of every schizophrenic
patient with positive symptoms is uncertain.A deficiency
in glutamate transmission that would impair appropriate
modulation of prefrontal-striatothalamic loops by affer-
ents from the amygdala-hippocampal complex is
another mechanism that might induce positive symp-
toms in the absence of overactivity of DA transmis-
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sion.
12,68,97 In other words, endogenous sensitization of
dopaminergic systems might represent only one avenue,
among others, leading to chronic and/or recurrent psy-
chotic episodes.
Implications for treatment
The model proposed here involves a three-step process,in
which neurodevelopmental abnormalities associated with
schizophrenia set the stage for sensitization of DA sys-
tems. Sustained hyperactivity of DA neurons resulting
from this sensitization process leads to neuroplastic
changes downstream from the DA synapse (Figure 4).
This neuroplastic adaptation underlies the psychotic expe-
rience. If untreated, activities in these aberrant circuits
become independent from increased DA activity.On the
other hand,early treatment will reverse these neuroplas-
tic changes and induce an extinction of the sensitization
process.In other words,it might be important to evaluate
the role of DA in schizophrenia within the context of a
brain with a history, divided into a predopaminergic, a
dopaminergic,and a postdopaminergic era.
This model clearly supports the rationale for D2 block-
ade during periods of illness exacerbation,and the need
for early intervention during prodromal states. It also
suggests the need for new relapse prevention strategies.
Currently,pharmacological “maintenance”during remis-
sion phases is based on dopaminergic D2 receptor block-
ade.These treatments succeed at preventing the reemer-
gence of sensitization and at reducing the risk of relapse.
Yet, they exert their preventive effect at the price of
inducing a hypodopaminergic state, which is associated
with significant adverse effects and a lower quality of
life. A better understanding of the neurobiological
mechanisms that trigger the reemergence of sensitiza-
tion might lead to new relapse prevention strategies
sparing D2 receptor function.In other words,the appar-
ent normality of DA transmission during illness remis-
sion might be a more important finding of these studies
than the dysregulation during illness exacerbation.
GLU GLU
Prefontal cortex
Nucleus
accumbens
Hippocampus
Basolateral amygdala
Ventral tegmental area
Mediodorsal
nucleus
Ventral
pallidum
GABA
GLU
DA
GABA
Figure 3. Schematic representation of ventral limbic circuits implicated in the positive symptoms of schizophrenia (adapted from reference 96).
The nucleus accumbens receives major excitatory inputs from the prefrontal cortex (PFC), basolateral amygdala, and hippocampus, and
dopamine (DA) input from the ventral tegmental area (VTA). The nucleus accumbens sends inputs to the ventral pallidum, which, among
others, sends inputs to the mediodorsal nucleus of the thalamus. The mediodorsal nucleus provides excitatory inputs back to the PFC.
The nucleus accumbens is a crucial node in this circuit, where inputs from the PFC are gated by excitatory projections from the hip-
pocampus and the basolateral amygdala, and DA projections from the VTA. It is proposed that increased DA activity induces perturba-
tion in the information flow within this circuit, in the modulation of this information by hippocampus and amygdala, and in the gating
of sensory information by the thalamus. If sustained, the increase in DA activity might lead to neuroplastic changes in this circuit result-
ing in the emergence of a psychotic experience. GLU: glutamate; GABA: γ -aminobutyric acid.Dopamine imaging in schizophrenia - Laruelle and Abi-Dargham Dialogues in Clinical Neuroscience - Vol 2 . No.4 . 2000
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Moreover, this model calls for better understanding of
the long-term consequences of exaggerated stimulation of
D2 receptors on cortico-subcortical connectivity. The
observation that, in some patients, psychotic symptoms
are independent of DA transmission (these symptoms
are experienced in the presence of apparently normal
levels of synaptic DA and show little or no response to D2
receptor blockade) is another fundamental observation
from these imaging studies.This observation supports the
need for the development of new therapeutic approaches.
Finally,it should be reemphasized that the presence of
positive symptoms is only one aspect of the sympto-
matology presented by these patients.While they might
be the most visible expression of the illness, these
symptoms are not the most enduring nor the ones asso-
ciated with most disability, at least in the postneu-
roleptic era.Cognitive impairments appear to precede
and outlive psychotic episodes,and their severity is one
of the best predictors of poor outcome.
6 While the
brain-imaging studies reported here supported the role
of subcortical hyperdopaminergic activity in the patho-
physiology of positive symptoms, the potential role of
Figure 4. Model describing the role of subcortical dopamine (DA) dysregulation in the chain of events leading to clinical expression of positive
symptoms in schizophrenia. It is postulated that neurodevelopmental abnormalities, resulting from complex interactions of genetic vul-
nerability and pre- or perinatal insults, induce, among other consequences, impaired regulation of subcortical DA activity by the pre-
frontal cortex (Figure 2). The lack of normal buffering systems results in vulnerability of DA systems to develop a process of endogenous
sensitization. Excessive DA activity, initially as a response to stress, initiates a positive feedback loop, in which elevated DA activity becomes
self-sustained even in the absence of stressors or other salient stimuli. This excessive DA activity perturbs information flow in cortico-
striatothalamocortical loops (Figure 3), which results over time in remodeling of these circuits. The hypothetical neuroplastic response
to DA hyperactivity mediates alterations of information processing leading to a psychotic episode. D2 receptor blockade not only recal-
ibrates DA responsivity by interrupting the endogenous DA process, but also reverses the neuroplastic changes that took place down-
stream from the DA synapse. However, in the absence of treatment, these neuroplastic changes become progressively “hard-wired,”
and activity in these reentrant psychotic ensembles becomes independent of sustained DA activity and unresponsive to D2 receptor block-
ade. While this model integrates observations from brain-imaging studies of DA synaptic activity in schizophrenia, its speculative nature
must be emphasized. Furthermore, this does not imply that this chain of events is the only avenue leading to the emergence of psy-
chotic symptoms in the schizophrenic brain. Nonetheless, it provides a number of testable hypotheses and directions for future research. 
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La dopamina en la historia del cerebro
esquizofrénico: contribuciones recientes 
de los estudios de neuroimágenes
Los desarrollos recientes de las imágenes de la
tomografía de emisión de positrones (“PET”) y de
la tomografía computerizada de emisión de
fotones únicos (“SPECT”) han permitido la medi-
ción de la transmisión dopaminérgica en los
receptores D2 del cerebro humano en vivo. Los
estudios que han utilizado estas técnicas han
demostrado que el aumento de la estimulación
dopaminérgica de los receptores D2 estriatales en
la esquizofrenia está asociada con el primer epi-
sodio de la enfermedad y los episodios poste-
riores de exacerbación del cuadro. Aun cuando
esta disrregulación de la función dopaminérgica
no está asociada con la severidad de los síntomas
positivos per se, el aumento de la actividad dopa-
minérgica sináptica es predictora de una buena
respuesta terapéutica al tratamiento antipsicóti-
co. Durante los períodos de remisión de la enfer-
medad no se han detectado anormalidades de la
función dopaminérgica. Estos hallazgos están
integrados en un modelo clínico que propone
que en la esquizofrenia las anormalidades del
neurodesarrollo de las conexiones cortico-subcor-
ticales se traducen en una vulnerabilidad del sis-
tema dopaminérgico mesolímbico para el desar-
rollo de un proceso de sensibilización endógeno,
y la consecuente hiperestimulación mantenida de
los receptores D2 induce cambios neuroplásticos
dentro de los circuitos cortico-estriatales/ tálamo-
corticales, que afectan los procesos de informa-
ción y la experiencia psicótica subyacente.
Dopamine et cerveau schizophrénique :
contributions récentes des études 
d’imagerie cérébrale
Les progrès récents de la tomographie par émis-
sion de positron (TEM) et de la tomographie par
émission de simple photon ont permis de réaliser
des mesures fonctionnelles de la transmission de
la dopamine (DA) au niveau des récepteurs D2
dans le cerveau humain vivant. Les études utili-
sant ces techniques ont démontré qu’au cours de
la schizophrénie tant l'épisode inaugural que les
épisodes ultérieurs d'exacerbation de la maladie
sont associés à une augmentation de la stimula-
tion dopaminergique des récepteurs D2 striataux.
Alors que ce trouble de la régulation de la fonc-
tion dopaminergique n'est pas en soi associé à la
sévérité des symptômes positifs, l'augmentation
de l’activité synaptique de la DA est en revanche
prédictive d’une réponse thérapeutique positive
au traitement antipsychotique. En outre, aucun
trouble de la fonction dopaminergique n'est
détecté au cours des périodes de rémission de la
maladie. Un modèle clinique de la schizophrénie
intégrant ces données est proposé selon lequel,
d'une part, les anomalies neurodéveloppemen-
tales des connexions cortico-sous-corticales se tra-
duiraient par une vulnérabilité du système méso-
limbique dopaminergique au développement
d’un processus de sensibilisation endogène, et
d’autre part, l'hyperstimulation prolongée résul-
tante des récepteurs D2 induirait des modifica-
tions neuroplastiques au sein des circuits cortico-
striato-thalamo-corticaux, perturbant le traitement
des informations et sous-tendant l'expérience psy-
chotique.
prefrontal deficit in DA transmission in the patho-
physiology of cognitive impairment remains to be
firmly established. The development of new brain-
imaging techniques enabling the study of prefrontal
DA transmission is warranted to further explore this
other face of the dopaminergic imbalance hypothesis of
schizophrenia.❑
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